Alpha Tau Medical, Tolmar International Agree to Develop, Commercialize Prostate Cancer Therapy

MT Newswires Live06-03

Alpha Tau Medical (DRTS) and Tolmar International have agreed to develop and commercialize Alpha DaRT therapy for the treatment of prostate cancer in the US, the companies said Wednesday.

Under the agreement, Alpha Tau will lead clinical development and manufacture the therapy, while Tolmar International will receive exclusive rights it in the US, according to the companies.

Additionally, the companies said Tolmar International will make a $20 million equity investment in Alpha Tau at $11.99 per share and provide $15 million towards a new US manufacturing facility.

The deal also includes up to $96.5 million in development and regulatory milestones and up to $65 million in commercial milestone payments for the initial indication, Alpha Tau Medical and Tolmar International said.

Alpha Tau said it will sell Alpha DaRT to Tolmar at 60% of onward net sales price, subject to certain adjustments.

Alpha Tau Medical shares were over 15% higher in early Wednesday trading.

Price: 10.31, Change: +1.38, Percent Change: +15.45

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2640900394?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-03 22:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640900394","market":"sh","top_or_hot":-1,"title":"Alpha Tau Medical, Tolmar International Agree to Develop, Commercialize Prostate Cancer Therapy","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/DRTS\">Alpha Tau Medical</a> (DRTS) and Tolmar International have agreed to develop and commercialize Alpha DaRT therapy for the treatment of prostate cancer in the US, the companies said Wednesday.</p><p>Under the agreement, <a href=\"https://laohu8.com/S/DRTSW\">Alpha Tau</a> will lead clinical development and manufacture the therapy, while Tolmar International will receive exclusive rights it in the US, according to the companies.</p><p>Additionally, the companies said Tolmar International will make a $20 million equity investment in Alpha Tau at $11.99 per share and provide $15 million towards a new US manufacturing facility.</p><p>The deal also includes up to $96.5 million in development and regulatory milestones and up to $65 million in commercial milestone payments for the initial indication, Alpha Tau Medical and Tolmar International said.</p><p>Alpha Tau said it will sell Alpha DaRT to Tolmar at 60% of onward net sales price, subject to certain adjustments.</p><p>Alpha Tau Medical shares were over 15% higher in early Wednesday trading.</p><p>Price: 10.31, Change: +1.38, Percent Change: +15.45</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alpha Tau Medical, Tolmar International Agree to Develop, Commercialize Prostate Cancer Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlpha Tau Medical, Tolmar International Agree to Develop, Commercialize Prostate Cancer Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-03 22:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/DRTS\">Alpha Tau Medical</a> (DRTS) and Tolmar International have agreed to develop and commercialize Alpha DaRT therapy for the treatment of prostate cancer in the US, the companies said Wednesday.</p><p>Under the agreement, <a href=\"https://laohu8.com/S/DRTSW\">Alpha Tau</a> will lead clinical development and manufacture the therapy, while Tolmar International will receive exclusive rights it in the US, according to the companies.</p><p>Additionally, the companies said Tolmar International will make a $20 million equity investment in Alpha Tau at $11.99 per share and provide $15 million towards a new US manufacturing facility.</p><p>The deal also includes up to $96.5 million in development and regulatory milestones and up to $65 million in commercial milestone payments for the initial indication, Alpha Tau Medical and Tolmar International said.</p><p>Alpha Tau said it will sell Alpha DaRT to Tolmar at 60% of onward net sales price, subject to certain adjustments.</p><p>Alpha Tau Medical shares were over 15% higher in early Wednesday trading.</p><p>Price: 10.31, Change: +1.38, Percent Change: +15.45</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2640900394","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640900394","pubTimestamp":1780495418,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Alpha Tau Medical (DRTS) and Tolmar International have agreed to develop and commercialize Alpha DaRT therapy for the treatment of prostate cancer in the US, the companies said Wednesday.Under the agr","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","ADC":"艾格里房产","BK4231":"零售房地产信托","DRTS":"Alpha Tau Medical","BK4080":"零售业房地产投资信托"},"translate_title":"Alpha Tau Medical和Tolmar International同意开发和商业化前列腺癌疗法","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DRTS":1.5,"ADC":1.5},"content_text":"Alpha Tau Medical (DRTS) and Tolmar International have agreed to develop and commercialize Alpha DaRT therapy for the treatment of prostate cancer in the US, the companies said Wednesday.Under the agreement, Alpha Tau will lead clinical development and manufacture the therapy, while Tolmar International will receive exclusive rights it in the US, according to the companies.Additionally, the companies said Tolmar International will make a $20 million equity investment in Alpha Tau at $11.99 per share and provide $15 million towards a new US manufacturing facility.The deal also includes up to $96.5 million in development and regulatory milestones and up to $65 million in commercial milestone payments for the initial indication, Alpha Tau Medical and Tolmar International said.Alpha Tau said it will sell Alpha DaRT to Tolmar at 60% of onward net sales price, subject to certain adjustments.Alpha Tau Medical shares were over 15% higher in early Wednesday trading.Price: 10.31, Change: +1.38, Percent Change: +15.45","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2640900394","isCrawlerRequest":true}